派罗欣联合利巴韦林抗病毒治疗对Ⅰb型慢性丙肝的临床疗效观察

Clinical efficacy of pegasys and ribavirin antiviral therapy for chronic hepatitis C in Ⅰb

目的:探究派罗欣联合利巴韦林抗病毒治疗对Ⅰb型慢性丙肝的临床疗效观察。方法:对照组给予干扰素-α-1b联合利巴韦林治疗,观察组给予派罗欣联合利巴韦林治疗,观察对比两组临床疗效、复发情况及药物不良反应情况。结果:观察组早期应答率86.5%,明显高于对照组的70.3%,P<0.05;观察组无效率5.4%,复发率5.4%,均分别低于对照组的24.3%和18.9%,组间比较差具有统计学意,P均<0.05。两组不良反应比较差异无统计学意义,P>0.05。结论:派罗欣联合利巴韦林治疗Ⅰb型慢性丙肝病毒的临床疗效确切,早期应答率较高,复发率较低,且用药安全,可作为临床首选治疗方案。

Objective:To explore the clinical efficacy of pegasys and ribavirin antiviral therapy for chronic hepatitis C in Ⅰb. Methods:The control group received-α-1b interferon and ribavirin,the observation group received pegasys and ribavirin,two groups were observed and compared the clinical efficacy,recurrence and adverse drug reactions.Results:Early response rate of the observation group was 86.5%,significantly higher than the control group 70.3%,P<0.05;the ineffective rate of the observation group was 5.4%,the recurrence rate was 5.4%,were lower than those in the control group 24.3% and 18.9%,there was statistically significant,P<0.05.There is no significant difference between two groups of adverse reaction,P>0.05.Conclusion:There is good clinical efficacy of pegasys and ribavirin antiviral therapy for chronic hepatitis C in Ⅰ b,early response rate is higher,the recurrence rate is low,and the safety of drug use,can be used as the preferred clinical treatment.